Original Research

Published on 11 Mar 2021

Characteristics of T-Cell Receptor Repertoire and Correlation With EGFR Mutations in All Stages of Lung Cancer

in Cancer Immunity and Immunotherapy

Huaxia Yang
Yadong Wang
Ziqi Jia
Yanyu Wang
Xiaoying Yang
Pancheng Wu
Yang Song
Huihui Xu
Dejian Gu
Rongrong Chen

Frontiers in Oncology

doi 10.3389/fonc.2021.537735

4,886 views
12 citations

Original Research

Published on 10 Mar 2021

Combination of Interleukin-15 With a STING Agonist, ADU-S100 Analog: A Potential Immunotherapy for Prostate Cancer

in Cancer Immunity and Immunotherapy

Ana M. Esteves
Efthymia Papaevangelou
Prokar Dasgupta
Christine Galustian

Frontiers in Oncology

doi 10.3389/fonc.2021.621550

8,009 views
24 citations

Original Research

Published on 10 Mar 2021

Bispecific c-Met/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma

in Cancer Immunity and Immunotherapy

Wei Jiang
Tao Li
Jiaojiao Guo
Jingjing Wang
Lizhou Jia
Xiao shi
Tingting Yang
Ruonan Jiao
Xin Wei
Zhenqing Feng

Frontiers in Oncology

doi 10.3389/fonc.2021.546586

9,375 views
55 citations

Review

Published on 09 Mar 2021

Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab

in Cancer Immunity and Immunotherapy

Amirali Karimi
Sanam Alilou
Hamid Reza Mirzaei

Frontiers in Oncology

doi 10.3389/fonc.2021.624780

5,567 views
17 citations

Original Research

Published on 05 Mar 2021

Progression Patterns, Treatment, and Prognosis Beyond Resistance of Responders to Immunotherapy in Advanced Non-Small Cell Lung Cancer

in Cancer Immunity and Immunotherapy

Yanjun Xu
Hui Li
Yun Fan

Frontiers in Oncology

doi 10.3389/fonc.2021.642883

7,924 views
34 citations

Original Research

Published on 03 Mar 2021

Chimeric Antigen Receptor T Cells Targeting Integrin αvβ6 Expressed on Cholangiocarcinoma Cells

in Cancer Immunity and Immunotherapy

Nattaporn Phanthaphol
Chalermchai Somboonpatarakun
Kwanpirom Suwanchiwasiri
Thaweesak Chieochansin
Jatuporn Sujjitjoon
Sopit Wongkham
John Maher
Mutita Junking
Pa-thai Yenchitsomanus

Frontiers in Oncology

doi 10.3389/fonc.2021.657868

7,812 views
33 citations

Original Research

Published on 03 Mar 2021

Identification of an Individualized Immune-Related Prognostic Risk Score in Lung Squamous Cell Cancer

in Cancer Immunity and Immunotherapy

Yuan Zhuang
Sihan Li
Chang Liu
Guang Li

Frontiers in Oncology

doi 10.3389/fonc.2021.546455

2,685 views
12 citations

Original Research

Published on 03 Mar 2021

Plinabulin, a Distinct Microtubule-Targeting Chemotherapy, Promotes M1-Like Macrophage Polarization and Anti-tumor Immunity

in Cancer Immunity and Immunotherapy

Marina Natoli
Petra Herzig
Elham Pishali Bejestani
Melanie Buchi
Reto Ritschard
G. Kenneth Lloyd
Ramon Mohanlal
James R. Tonra
Lan Huang
Viola Heinzelmann

Frontiers in Oncology

doi 10.3389/fonc.2021.644608

9,170 views
23 citations

Original Research

Published on 02 Mar 2021

The Identification and Validation of Two Heterogenous Subtypes and a Risk Signature Based on Ferroptosis in Hepatocellular Carcinoma

in Cancer Immunity and Immunotherapy

Zaoqu Liu
Libo Wang
Long Liu
Taoyuan Lu
Dechao Jiao
Yuling Sun
Xinwei Han

Frontiers in Oncology

doi 10.3389/fonc.2021.619242

10,303 views
48 citations

Case Report

Published on 26 Feb 2021

Case Report: Complete Response of Recurrent and Metastatic Cystadenocarcinoma of the Parotid Gland With a Single Course of Combined Nivolumab and Ipilimumab Therapy

in Cancer Immunity and Immunotherapy

Yoshiyuki Nakamura
Masahiro Nakayama
Bungo Nishimura
Naoko Okiyama
Ryota Tanaka
Yosuke Ishitsuka
Shin Matsumoto
Yasuhiro Fujisawa

Frontiers in Oncology

doi 10.3389/fonc.2021.618201

1,912 views
5 citations

Mini Review

Published on 26 Feb 2021

Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer

in Cancer Immunity and Immunotherapy

Dan Pu
Liyuan Yin
Lin Huang
Changlong Qin
Yuwen Zhou
Qiang Wu
Yan Li
Qinghua Zhou
Lu Li

Frontiers in Oncology

doi 10.3389/fonc.2021.637504

14,595 views
69 citations

Systematic Review

Published on 25 Feb 2021

Association of Survival and Immune-Related Adverse Events With Anti-PD-1/PD-L1 and Anti-CTLA-4 Inhibitors, Alone or Their Combination for the Treatment of Cancer: A Systematic Review and Meta-Analysis of 13 Clinical Trials

in Cancer Immunity and Immunotherapy

Leyin Zhang
Leitao Sun
Yiwen Zhou
Jieru Yu
Yingying Lin
Harpreet S. Wasan
Minhe Shen
Shanming Ruan

Frontiers in Oncology

doi 10.3389/fonc.2021.575457

3,862 views
8 citations

Original Research

Published on 25 Feb 2021

Immunotherapy-Associated Pancreatic Adverse Events: Current Understanding of Their Mechanism, Diagnosis, and Management

in Cancer Immunity and Immunotherapy

Ya Liu
Hao Zhang
Li Zhou
Weichun Li
Le Yang
Wen Li
Kezhou Li
Xubao Liu

Frontiers in Oncology

doi 10.3389/fonc.2021.627612

16,443 views
39 citations

Original Research

Published on 25 Feb 2021

PD-L2 Is Constitutively Expressed in Normal and Malignant Urothelium

in Cancer Immunity and Immunotherapy

Alexander C. Dowell
Haydn Munford
Anshita Goel
Naheema S. Gordon
Nicholas D. James
K. K. Cheng
Maurice P. Zeegers
Douglas G. Ward
Richard T. Bryan

Frontiers in Oncology

doi 10.3389/fonc.2021.626748

3,803 views
9 citations

Original Research

Published on 24 Feb 2021

Systemic Immune-Inflammation Index and Changes of Neutrophil-Lymphocyte Ratio as Prognostic Biomarkers for Patients With Pancreatic Cancer Treated With Immune Checkpoint Blockade

in Cancer Immunity and Immunotherapy

Jin Shang
Xiao Han
Haoran Zha
Haitao Tao
Xiaoyan Li
Fang Yuan
Guangying Chen
Lijie Wang
Junxun Ma
Yi Hu

Frontiers in Oncology

doi 10.3389/fonc.2021.585271

4,535 views
35 citations

Review

Published on 22 Feb 2021

Mitochondria’s Role in the Maintenance of Cancer Stem Cells in Glioblastoma

in Cancer Immunity and Immunotherapy

Yasaman Iranmanesh
Biao Jiang
Okoye C. Favour
Zhangqi Dou
Jiawei Wu
Jinfan Li
Chongran Sun

Frontiers in Oncology

doi 10.3389/fonc.2021.582694

10,487 views
36 citations

Navigation group

Articles

Characteristics of T-Cell Receptor Repertoire and Correlation With EGFR Mutations in All Stages of Lung Cancer

Combination of Interleukin-15 With a STING Agonist, ADU-S100 Analog: A Potential Immunotherapy for Prostate Cancer

Bispecific c-Met/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma

Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab

Progression Patterns, Treatment, and Prognosis Beyond Resistance of Responders to Immunotherapy in Advanced Non-Small Cell Lung Cancer

Chimeric Antigen Receptor T Cells Targeting Integrin αvβ6 Expressed on Cholangiocarcinoma Cells

Identification of an Individualized Immune-Related Prognostic Risk Score in Lung Squamous Cell Cancer

Plinabulin, a Distinct Microtubule-Targeting Chemotherapy, Promotes M1-Like Macrophage Polarization and Anti-tumor Immunity

The Identification and Validation of Two Heterogenous Subtypes and a Risk Signature Based on Ferroptosis in Hepatocellular Carcinoma

Case Report: Complete Response of Recurrent and Metastatic Cystadenocarcinoma of the Parotid Gland With a Single Course of Combined Nivolumab and Ipilimumab Therapy

Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer

Association of Survival and Immune-Related Adverse Events With Anti-PD-1/PD-L1 and Anti-CTLA-4 Inhibitors, Alone or Their Combination for the Treatment of Cancer: A Systematic Review and Meta-Analysis of 13 Clinical Trials

Immunotherapy-Associated Pancreatic Adverse Events: Current Understanding of Their Mechanism, Diagnosis, and Management

PD-L2 Is Constitutively Expressed in Normal and Malignant Urothelium

Systemic Immune-Inflammation Index and Changes of Neutrophil-Lymphocyte Ratio as Prognostic Biomarkers for Patients With Pancreatic Cancer Treated With Immune Checkpoint Blockade

Mitochondria’s Role in the Maintenance of Cancer Stem Cells in Glioblastoma